Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.

@article{Millan2006MultitargetSF,
  title={Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.},
  author={Mark J Millan},
  journal={Pharmacology \& therapeutics},
  year={2006},
  volume={110 2},
  pages={
          135-370
        }
}
  • M. Millan
  • Published 1 May 2006
  • Psychology, Biology
  • Pharmacology & therapeutics
On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal.
  • M. Millan
  • Biology, Psychology
    The international journal of neuropsychopharmacology
  • 2014
TLDR
The rationale underpinning multi-modal approaches for treating depression is outlined, the pros and cons of established and potentially novel multi-target vs. polypharmaceutical treatments are critically compared, and the former appear the most promising for the elaboration, development and clinical implementation of innovative concepts for the more effective management of depression.
The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
TLDR
The role of the melatonergic system in MDD is summarized, some data suggest that agomelatine has not only antidepressant effects but also anxiolytic effects, with a potential benefit both on anxiety symptoms associated with MDD and in the treatment of generalised anxiety disorder.
Pharmacogenetics of antidepressive drugs: a way towards personalized treatment of major depressive disorder.
  • S. Weizman, X. Gonda, P. Dome, G. Faludi
  • Psychology, Medicine
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology
  • 2012
TLDR
Genetic polymorphisms that may be involved in the therapeutic effects and side effects of antidepressive medications and which, in the future, may guide customized selection of the pharmacotherapeutic regimen in case of each patient are reviewed.
Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited
TLDR
This article reviews the development of new broad-spectrum antidepressants, the triple reuptake inhibitors, which also increase brain dopamine levels and proposes a hypothetical model: ‘the monoamine hypothesis revisited’ to predict what kind of pharmacological treatment will be effective in the different subtypes of depression.
Faster, better, stronger: towards new antidepressant therapeutic strategies.
...
...

References

SHOWING 1-10 OF 3,693 REFERENCES
From monoamines to genomic targets: a paradigm shift for drug discovery in depression
TLDR
The different phases of antidepressant drug discovery in the past, present and future are covered, and the challenges and opportunities for antidepressant research are commented on.
Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future
TLDR
A review of current pharmacotherapeutic options for major depressive disorder, current understanding of the neurobiology and pathogenesis of MDD, and a review of new and promising directions in pharmacological research will be provided.
The pharmacology of putative early-onset antidepressant strategies
  • P. Blier
  • Psychology, Biology
    European Neuropsychopharmacology
  • 2003
Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers
TLDR
The task of developing novel medications for bipolar disorder is truly daunting, and it is hopeful that understanding the mechanism of action of current mood stabilizers will ultimately lead clinical trials with more specific medications and thus better treatments those who suffer from this devastating illness.
Dual Monoamine Modulation for Improved Treatment of Major Depressive Disorder
TLDR
Clinical evidence suggests that a number of novel antidepressant drugs, including mirtazapine, milnacipran, venlafaxine, and duloxetine have been developed and may offer improved efficacy and/or faster onset of action compared with SSRIs and an improved side effect profile compared with TCAs.
...
...